Literature DB >> 11050451

Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options.

G R Kaufmann1, D A Cooper.   

Abstract

Recently, studies have shown that non-nucleoside reverse transcriptase inhibitors, such as efavirenz or nevirapine, in combination with two nucleoside analogues have an antiretroviral potency comparable to protease inhibitor containing regimens. Triple combination therapy that includes a non-nucleoside reverse transcriptase inhibitor can therefore be regarded as an effective alternative first-line treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050451     DOI: 10.1016/s1369-5274(00)00131-4

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  10 in total

1.  Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Lian-Qi Sun; Bingjie Qin; Li Huang; Keduo Qian; Chin-Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem Lett       Date:  2012-02-24       Impact factor: 2.823

2.  Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.

Authors:  Zhi-Yuan Wu; Na Liu; Bingjie Qin; Li Huang; Fei Yu; Keduo Qian; Susan L Morris-Natschke; Shibo Jiang; Chin Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  ChemMedChem       Date:  2014-06-04       Impact factor: 3.466

3.  Near-infrared investigations of novel anti-HIV tenofovir liposomes.

Authors:  Ahmed S Zidan; Crystal Spinks; Joseph Fortunak; Muhammad Habib; Mansoor A Khan
Journal:  AAPS J       Date:  2010-03-03       Impact factor: 4.009

4.  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Authors:  Yven Van Herrewege; Guido Vanham; Jo Michiels; Katrien Fransen; Luc Kestens; Koen Andries; Paul Janssen; Paul Lewi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.

Authors:  Giada A Locatelli; Giuseppe Campiani; Reynel Cancio; Elena Morelli; Anna Ramunno; Sandra Gemma; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

6.  Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.

Authors:  Hong-Wang Zhang; Steven J Coats; Lavanya Bondada; Franck Amblard; Mervi Detorio; Ghazia Asif; Emilie Fromentin; Sarah Solomon; Aleksandr Obikhod; Tony Whitaker; Nicolas Sluis-Cremer; John W Mellors; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2009-11-13       Impact factor: 2.823

7.  Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

Authors:  Kazuya Shimura; Eiichi Kodama; Yasuko Sakagami; Yuji Matsuzaki; Wataru Watanabe; Kazunobu Yamataka; Yasuo Watanabe; Yoshitsugu Ohata; Satoki Doi; Motohide Sato; Mitsuki Kano; Satoru Ikeda; Masao Matsuoka
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

8.  Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.

Authors:  Lian-Qi Sun; Lei Zhu; Keduo Qian; Bingjie Qin; Li Huang; Chin Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  J Med Chem       Date:  2012-08-10       Impact factor: 7.446

9.  Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.

Authors:  Na Liu; Lei Wei; Li Huang; Fei Yu; Weifan Zheng; Bingjie Qin; Dong-Qin Zhu; Susan L Morris-Natschke; Shibo Jiang; Chin-Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  J Med Chem       Date:  2016-04-12       Impact factor: 7.446

10.  Low dose adrenocorticotropic hormone test and adrenal insufficiency in critically ill acquired immunodeficiency syndrome patients.

Authors:  P K Shashidhar; G V Shashikala
Journal:  Indian J Endocrinol Metab       Date:  2012-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.